Shuttle Pharma appoints new Chairman to its Board

GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a micro-cap pharmaceutical company with a market capitalization of $1.85 million specializing in the development of treatments to enhance cancer radiation therapy, announced today the appointment of George Scorsis as its new Chairman of the Board of Directors. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 2.78, though it faces profitability challenges in its development stage. George Scorsis, who joined the company’s board in February 2025, brings over two decades of leadership experience in highly regulated sectors, including his tenure at Mettrum Health Corp. and Liberty Health Sciences.

Scorsis’s extensive background involves steering companies through periods of significant growth. His previous roles include President of Mettrum Health Corp., a prominent Canadian cannabis distributor, from October 2015 to July 2017, and CEO and Director of Liberty Health Sciences from July 2017 to February 2019. His appointment comes at a crucial time for SHPH, whose stock has experienced significant volatility, with InvestingPro analysis showing a 95.88% decline over the past year. He has also held the position of Chairman at SOL Global Investments Corp. and currently chairs both Entourage Health Corp. and AWAKN Life Sciences, which are traded on the TSX Venture Exchange and NEO Exchange, respectively.

In a statement, Scorsis expressed his commitment to Shuttle Pharma’s mission, emphasizing the potential impact of their radiation sensitizers on cancer cure rates and patient quality of life, particularly for those suffering from glioblastoma.

Shuttle Pharma’s focus is on the discovery and development of pharmaceuticals that improve radiation therapy outcomes for cancer patients. The company aims to enhance the effectiveness of radiation therapy while minimizing its side effects, potentially increasing cure rates and extending patient survival when used alone or in combination with other treatments, such as surgery, chemotherapy, and immunotherapy.

The announcement comes as Shuttle Pharma continues to develop its pipeline of treatments designed to work in conjunction with radiation therapy. While the company holds more cash than debt on its balance sheet, InvestingPro analysis reveals several additional financial metrics and insights available to subscribers. In line with federal securities laws, the company has cautioned that forward-looking statements in the press release are subject to various important factors that could cause actual results to differ materially from those indicated.

This news is based on a press release statement from Shuttle Pharmaceuticals Holdings, Inc.

In other recent news, Shuttle Pharmaceuticals Holdings, Inc. has announced a public offering of its common stock, aiming to raise approximately $5.75 million. The proceeds are intended to fund Phase II clinical trials for their lead product candidate, Ropidoxuridine, and for marketing and general corporate purposes. Additionally, the company has made significant progress in its Phase 2 clinical trial for Ropidoxuridine, with nearly 50% enrollment achieved and 84% of patients having completed all treatment cycles. Shuttle Pharma also filed a provisional patent application for a new prostate cancer therapy, marking a development in their diagnostic and therapeutic programs.

In another strategic move, Shuttle Pharmaceuticals signed a consulting agreement with Bowery Consulting Group to enhance its business strategies, including market messaging and growth strategies. Furthermore, the company appointed Christopher Cooper as interim Co-Chief Executive Officer to strengthen its business operations and capital markets presence. These developments underscore Shuttle Pharma’s ongoing efforts to improve cancer treatment outcomes through innovative therapies and strategic partnerships.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.